JBM (Healthcare) Limited
2161.HKHKSEHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
HK$1.91
HK$0.00 · 0.00%
2161.HK company overview
Regular session · HKT · Market data may be delayed.
Company profile
Company websiteJBM (Healthcare) Limited functions as an investment holding company that operates across Asia, engaging in the entire process of bringing healthcare and wellness products to market, from their conception and production to their promotion, distribution, and ultimate sale. The firm's offerings include a diverse range of consumer health products, such as its own branded traditional Chinese medicines – spanning everything from over-the-counter medications to specific medicated and non-medicated treatments. Additionally, it supplies diagnostic equipment and various pharmaceutical goods. Beyond manufacturing, JBM (Healthcare) is also involved in the buying, selling, and reselling (wholesale and retail) of Chinese medicines. Its business activities extend to the trade of medical supplies and pharmaceuticals, as well as the sale of general health and herbal products. Established in 2020, the company's main operations are directed from its headquarters in Kwun Tong, Hong Kong. JBM (Healthcare) Limited is a subsidiary entity of JBM Group (BVI) Limited.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Headquarters
- HK
- CEO
- Sum Kwong Yip
- Listed since
- Feb 5, 2021
- Employees
- 404
Market position
- Volume
- 12K
- 0.04× average
- Average volume
- 325.47K
- Average daily volume
- Market cap
- 1.56B HKD
- Beta
- 0.19
- Market reference 1
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 2.45B HKD
- P/E (TTM)
- 7.64×
- P/B (TTM)
- 1.45×
- P/S (TTM)
- 1.87×
- EV / EBITDA
- 8.06×
- Earnings yield
- 9.26%
- Free cash flow yield
- 5.50%
- Dividend yield
- 11.13%
Profitability & efficiency
- Gross margin
- 55.78%
- Operating margin
- 31.42%
- Net margin
- 24.09%
- Return on equity
- 18.62%
- Return on assets
- 11.41%
- Return on invested capital
- 12.91%
Financial health
- Debt / equity
- 0.36×
- Current ratio
- 1.9×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (HKD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 834.63M HKD | 782.29M HKD | 648.42M HKD | 520.32M HKD | 406.14M HKD |
| Cost of goods sold | 369.1M HKD | 368.59M HKD | 310.33M HKD | 332.4M HKD | 263.84M HKD |
| Gross profit | 465.54M HKD | 413.71M HKD | 338.08M HKD | 187.92M HKD | 142.3M HKD |
| Selling, general, and administrative | 211.85M HKD | 185.74M HKD | 180.21M HKD | 137.74M HKD | 125.15M HKD |
| Operating expenses | 211.85M HKD | 167.64M HKD | 163.88M HKD | 120.15M HKD | 105.94M HKD |
| Interest income | 800K HKD | 1.57M HKD | 762K HKD | 272K HKD | 18K HKD |
| Interest expense | 11.69M HKD | 4.46M HKD | 8.5M HKD | 8.21M HKD | 6.41M HKD |
| Depreciation and amortization | 49.74M HKD | 52.28M HKD | 46.52M HKD | 43.63M HKD | 47.78M HKD |
| Operating income | 253.69M HKD | 246.06M HKD | 174.21M HKD | 67.77M HKD | 36.36M HKD |
| Net income | 201.09M HKD | 197.26M HKD | 130.46M HKD | 57.09M HKD | 24.62M HKD |
Company facts updated Aug 24, 2026.
Earnings
- Latest EPS result
- 0.11
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Corporate actions
Annual dividends per share
Cash distributions grouped by calendar year; partial years are marked.
HK$0.2125
2025 complete year+257.1% since 2023
HK$0.0595
2,023
HK$0.0955
2,024
HK$0.2125
2,025
Corporate action history
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
DividendUpcoming | Sep 7, 2026 | HK$0.0735Semi-Annual | Sep 9, 2026 | Oct 5, 2026 |
Dividend | Nov 28, 2025 | HK$0.0975Semi-Annual | Dec 2, 2025 | Dec 17, 2025 |
Dividend | Aug 11, 2025 | HK$0.115Semi-Annual | Aug 13, 2025 | Aug 28, 2025 |
Dividend | Dec 17, 2024 | HK$0.055Semi-Annual | Dec 19, 2024 | Jan 15, 2025 |
Dividend | Aug 15, 2024 | HK$0.0405Semi-Annual | Aug 19, 2024 | Sep 17, 2024 |
Dividend | Dec 7, 2023 | HK$0.0345Semi-Annual | Dec 11, 2023 | Dec 28, 2023 |
Ex-dividend Sep 7, 2026
HK$0.0735
Semi-Annual
Record Sep 9, 2026 · Payment Oct 5, 2026
Ex-dividend Nov 28, 2025
HK$0.0975
Semi-Annual
Record Dec 2, 2025 · Payment Dec 17, 2025
Ex-dividend Aug 11, 2025
HK$0.115
Semi-Annual
Record Aug 13, 2025 · Payment Aug 28, 2025
Ex-dividend Dec 17, 2024
HK$0.055
Semi-Annual
Record Dec 19, 2024 · Payment Jan 15, 2025
Ex-dividend Aug 15, 2024
HK$0.0405
Semi-Annual
Record Aug 19, 2024 · Payment Sep 17, 2024
Ex-dividend Dec 7, 2023
HK$0.0345
Semi-Annual
Record Dec 11, 2023 · Payment Dec 28, 2023
2161.HK peers
ETFs holding 2161.HK
Funds reporting this stock among their holdings, ordered by reported position size.
Dimensional - International Small Cap ETFDFIS56.53K0.00%5.91B USD0.39%$37.545+0.71%
Dimensional World ex U.S. Core Equity 2 ETFDFAX43.99K0.00%12.57B USD0.28%$38.16+0.82%
Dimensional - International Core Equity 2 ETFDFIC42.57K0.00%15.43B USD0.22%$39.405+0.83%
Avantis International Equity ETFAVDE236.3—19.1B USD0.23%$94.26+0.87%Dimensional - International Small Cap ETFDFIS- Market value
- 56.53K
- Weight
- 0.00%
- AUM
- 5.91B USD
- Expense ratio
- 0.39%
- Price / 1D
- $37.545+0.71%
Dimensional World ex U.S. Core Equity 2 ETFDFAX- Market value
- 43.99K
- Weight
- 0.00%
- AUM
- 12.57B USD
- Expense ratio
- 0.28%
- Price / 1D
- $38.16+0.82%
Dimensional - International Core Equity 2 ETFDFIC- Market value
- 42.57K
- Weight
- 0.00%
- AUM
- 15.43B USD
- Expense ratio
- 0.22%
- Price / 1D
- $39.405+0.83%
Avantis International Equity ETFAVDE- Market value
- 236.3
- Weight
- —
- AUM
- 19.1B USD
- Expense ratio
- 0.23%
- Price / 1D
- $94.26+0.87%
Continue in GoAI
Research 2161.HKresearch.disclaimer